What the FDA labels say about taking them together
Oxaprozin and pemetrexed
Oxaprozin's FDA label of December 26, 2024 names pemetrexed in its drug interactions section; the pemetrexed labels PlainMeds reads (4) do not name oxaprozin. The oxaprozin label: “Concomitant use of oxaprozin and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the oxaprozin FDA label on DailyMed (effective December 26, 2024, Amneal Pharmaceuticals NY LLC); the pemetrexed FDA label on DailyMed (effective October 8, 2025, Avyxa Pharma, LLC).
What does the oxaprozin label say about pemetrexed?
Oxaprozin label, drug interactionsPemetrexed Clinical Impact: Concomitant use of oxaprozin and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of oxaprozin and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. …
Source: FDA drug label (Oxaprozin, NDA217927), SOLA Pharmaceuticals, LLC, effective December 3, 2025 (SPL set 450f5941-7f10-42fe-e063-6394a90a4803), via openFDA
Source: FDA drug label (Oxaprozin), Amneal Pharmaceuticals NY LLC, effective December 26, 2024 (SPL set d9b0ca6c-4c53-4f6e-918b-02a8c472a194), via openFDA; the full label on DailyMed
What does the pemetrexed label say about oxaprozin?
Pemetrexed's label (effective October 8, 2025) and its 3 other brand-application labels do not name oxaprozin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AXTLE), Avyxa Pharma, LLC, effective October 8, 2025 (SPL set 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oxaprozin | Pemetrexed | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis | Lung cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.475 per tablet 600 mg tablet | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once